MA52308A - Procédés et intermédiaires pour la préparation d'antagonistes c5ar - Google Patents
Procédés et intermédiaires pour la préparation d'antagonistes c5arInfo
- Publication number
- MA52308A MA52308A MA052308A MA52308A MA52308A MA 52308 A MA52308 A MA 52308A MA 052308 A MA052308 A MA 052308A MA 52308 A MA52308 A MA 52308A MA 52308 A MA52308 A MA 52308A
- Authority
- MA
- Morocco
- Prior art keywords
- intermediaries
- preparing
- methods
- c5ar antagonists
- c5ar
- Prior art date
Links
- 101150009981 C5AR1 gene Proteins 0.000 title 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462057107P | 2014-09-29 | 2014-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52308A true MA52308A (fr) | 2021-02-24 |
Family
ID=55583729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052308A MA52308A (fr) | 2014-09-29 | 2015-09-28 | Procédés et intermédiaires pour la préparation d'antagonistes c5ar |
Country Status (19)
Country | Link |
---|---|
US (5) | US9745268B2 (fr) |
EP (2) | EP3682879B1 (fr) |
JP (1) | JP6898229B6 (fr) |
KR (2) | KR102593431B1 (fr) |
CN (2) | CN113121415A (fr) |
AU (2) | AU2015324111B2 (fr) |
BR (1) | BR112017006232B1 (fr) |
CA (2) | CA3220371A1 (fr) |
DK (1) | DK3200791T3 (fr) |
ES (2) | ES2926828T3 (fr) |
IL (1) | IL251061B (fr) |
MA (1) | MA52308A (fr) |
MX (2) | MX368492B (fr) |
NZ (2) | NZ730123A (fr) |
PL (1) | PL3200791T3 (fr) |
PT (1) | PT3200791T (fr) |
RU (1) | RU2712233C2 (fr) |
SG (1) | SG11201702185UA (fr) |
WO (1) | WO2016053890A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101680818B1 (ko) | 2008-12-22 | 2016-11-29 | 케모센트릭스, 인크. | C5ar 길항제 |
WO2011163640A1 (fr) | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | Antagonistes de c5ar |
SG11201702185UA (en) * | 2014-09-29 | 2017-04-27 | Chemocentryx Inc | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
US20170202821A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
WO2019089468A1 (fr) * | 2017-10-30 | 2019-05-09 | Chemocentryx, Inc. | Composés deutérés utilisés comme immunomodulateurs |
MA52808A (fr) | 2018-06-07 | 2021-04-14 | Chemocentryx Inc | Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca |
MA54318B1 (fr) | 2018-11-30 | 2023-08-31 | Chemocentryx Inc | Formulations de capsules |
KR102207333B1 (ko) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | 4중 연속 고리 화합물의 신규한 제조방법 |
KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
CN114867473A (zh) | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
WO2022078269A1 (fr) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Forme cristalline d'avacopan, son procédé de préparation et son utilisation |
WO2022263263A1 (fr) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Forme cristalline d'avacopan |
EP4137133A1 (fr) | 2021-08-19 | 2023-02-22 | Sandoz AG | Forme cristalline d'avacopan |
CN113957106B (zh) * | 2021-11-03 | 2024-04-19 | 暨明医药科技(苏州)有限公司 | 一种Avacopan及其中间体的制备方法 |
CN114262291B (zh) * | 2022-01-04 | 2023-05-19 | 重庆医科大学 | 一种阿伐可泮的合成方法 |
WO2023158722A2 (fr) | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processus de préparation d'avacopan et de ses intermédiaires |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
MXPA01002173A (es) | 1998-08-28 | 2003-07-14 | Scios Inc | Inhibidores de p38-alfa cinasa. |
RU2197288C2 (ru) | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
AU2001259511A1 (en) | 2000-05-05 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
JP2004502672A (ja) * | 2000-06-29 | 2004-01-29 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症剤および免疫抑制剤としてのアリールフェニルシクロプロピルスルフィド誘導体およびその使用 |
US7105567B2 (en) | 2000-08-10 | 2006-09-12 | Mitsubishi Pharma Corporation | 3-substituted urea derivatives and medicinal use thereof |
KR100884709B1 (ko) | 2000-09-14 | 2009-02-19 | 미쓰비시 타나베 파마 코퍼레이션 | 신규한 아미드 유도체의 광학 활성체 및 그의 의약적 용도 |
JP5260818B2 (ja) | 2000-09-29 | 2013-08-14 | ノバルティス・インターナショナル・ファーマシューティカル・リミテッド | 高親和性低分子C5a受容体調節物質 |
SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
DE10293174D2 (de) | 2001-07-19 | 2004-07-01 | Luk Lamellen & Kupplungsbau | Übertragungsstrecke zum Ansteuern einer Kupplung |
ATE360441T1 (de) | 2001-08-17 | 2007-05-15 | Tanox Inc | Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen |
ATE424393T1 (de) | 2001-09-21 | 2009-03-15 | Mitsubishi Tanabe Pharma Corp | 3-substituierte 4-pyrimidonderivate |
ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
AU2003218374A1 (en) | 2002-03-28 | 2003-10-13 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
EP1487796A4 (fr) | 2002-03-28 | 2005-11-16 | Neurogen Corp | Biarylamides substitues en tant que modulateurs du recepteur c5a |
EP1490044A4 (fr) | 2002-03-29 | 2008-04-16 | Neurogen Corp | Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
WO2004014905A1 (fr) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes benzimidazole substitues |
WO2004018460A1 (fr) | 2002-08-21 | 2004-03-04 | Neurogen Corporation | Aminomethyl imidazoles en tant que modulateurs de recepteurs c5a |
FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2003290605A1 (en) | 2002-11-05 | 2004-06-03 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
EP1638935A1 (fr) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Antagoniste de nk1 |
US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
MXPA06014574A (es) | 2004-06-24 | 2007-03-12 | Incyte Corp | Piperidinas n-sustituidas y su uso como farmaceuticos. |
EP1621536A1 (fr) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Dérivés d'urées cycliques aminés, leur préparation et utilisation pharmaceutique en tant qu'inhibiteurs de Kinase |
WO2006071958A1 (fr) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Composes utilises comme antagonistes du recepteur de la chimiokine |
BRPI0607756A2 (pt) | 2005-02-18 | 2010-05-18 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos |
WO2007035428A1 (fr) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Inhibiteurs de la kinase met |
US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
DK1951663T3 (en) | 2005-11-24 | 2016-10-10 | Dompé Farm S P A | (r)-arylkylaminoderivater og farmaceutiske sammensætninger indeholdende dem |
AU2007225044C1 (en) | 2006-03-15 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
WO2008022060A2 (fr) | 2006-08-14 | 2008-02-21 | Novartis Ag | composés organiques et leurs utilisations |
WO2008053270A2 (fr) | 2006-10-31 | 2008-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation d'un antagoniste du récepteur egfr pour le traitement de la glomérulonéphrite |
KR20100027241A (ko) | 2007-06-29 | 2010-03-10 | 토렌트 파마슈티칼스 리미티드 | Hsp 인듀서로서 신규의 치환된 피페리돈 |
CA2737219C (fr) | 2008-08-11 | 2017-02-28 | Tracy Keller | Analogues d'halofuginone pour l'inhibition d'arnt synthetases et leurs utilisations |
EP2331561A4 (fr) | 2008-09-03 | 2013-02-27 | Xenome Ltd | Bibliothèques de conjugués peptidiques et leurs méthodes de fabrication |
US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
CN109045296A (zh) | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
KR101680818B1 (ko) | 2008-12-22 | 2016-11-29 | 케모센트릭스, 인크. | C5ar 길항제 |
US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
WO2011163640A1 (fr) | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | Antagonistes de c5ar |
AU2013277154A1 (en) | 2012-06-20 | 2014-12-18 | Jonathan E. Grob | Complement pathway modulators and uses thereof |
WO2014180961A1 (fr) | 2013-05-08 | 2014-11-13 | Novo Nordisk A/S | Utilisation d'antagonistes de c5ar |
SG11201702185UA (en) * | 2014-09-29 | 2017-04-27 | Chemocentryx Inc | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
US20170202821A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
EP3439658B1 (fr) | 2016-04-04 | 2021-11-24 | ChemoCentryx, Inc. | Antagonistes de c5ar solubles |
CA3205474A1 (fr) | 2020-12-21 | 2022-06-30 | Chemocentryx, Inc. | Traitement de la glomerulopathie a c3 a l'aide d'un inhibiteur de c5a |
-
2015
- 2015-09-28 SG SG11201702185UA patent/SG11201702185UA/en unknown
- 2015-09-28 BR BR112017006232-1A patent/BR112017006232B1/pt active IP Right Grant
- 2015-09-28 KR KR1020177011789A patent/KR102593431B1/ko active IP Right Grant
- 2015-09-28 WO PCT/US2015/052697 patent/WO2016053890A1/fr active Application Filing
- 2015-09-28 KR KR1020237035689A patent/KR20230149873A/ko active Application Filing
- 2015-09-28 ES ES20160995T patent/ES2926828T3/es active Active
- 2015-09-28 RU RU2017114960A patent/RU2712233C2/ru active
- 2015-09-28 AU AU2015324111A patent/AU2015324111B2/en active Active
- 2015-09-28 NZ NZ730123A patent/NZ730123A/en unknown
- 2015-09-28 PT PT158456103T patent/PT3200791T/pt unknown
- 2015-09-28 DK DK15845610.3T patent/DK3200791T3/da active
- 2015-09-28 PL PL15845610T patent/PL3200791T3/pl unknown
- 2015-09-28 ES ES15845610T patent/ES2802428T3/es active Active
- 2015-09-28 JP JP2017516679A patent/JP6898229B6/ja active Active
- 2015-09-28 CN CN202110432100.1A patent/CN113121415A/zh active Pending
- 2015-09-28 NZ NZ767823A patent/NZ767823A/en unknown
- 2015-09-28 MA MA052308A patent/MA52308A/fr unknown
- 2015-09-28 CA CA3220371A patent/CA3220371A1/fr active Pending
- 2015-09-28 MX MX2017003789A patent/MX368492B/es active IP Right Grant
- 2015-09-28 EP EP20160995.5A patent/EP3682879B1/fr active Active
- 2015-09-28 US US14/867,669 patent/US9745268B2/en active Active
- 2015-09-28 EP EP15845610.3A patent/EP3200791B1/fr active Active
- 2015-09-28 CN CN201580052937.6A patent/CN106999481B/zh active Active
- 2015-09-28 CA CA2960733A patent/CA2960733C/fr active Active
-
2017
- 2017-03-09 IL IL251061A patent/IL251061B/en active IP Right Grant
- 2017-03-23 MX MX2019011911A patent/MX2019011911A/es unknown
- 2017-07-25 US US15/659,468 patent/US10266492B2/en active Active
-
2019
- 2019-03-21 US US16/360,195 patent/US10532982B2/en active Active
- 2019-12-06 US US16/706,296 patent/US20200354320A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204209A patent/AU2021204209B2/en active Active
-
2022
- 2022-02-08 US US17/667,289 patent/US11845729B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52308A (fr) | Procédés et intermédiaires pour la préparation d'antagonistes c5ar | |
HK1243104A1 (zh) | 抗fgfr2/3抗體及其使用方法 | |
HK1249023A1 (zh) | Pd-l1("程序性死亡配體1")抗體 | |
HK1253306A1 (zh) | 抗ntb-a抗體及相關組合物和方法 | |
ZA201605154B (en) | Insecticidal proteins and methods for their use | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
EP3148729A4 (fr) | Microparticules revêtues d'un hydrure, et procédés pour leur fabrication | |
ZA201702161B (en) | Insecticidal proteins and methods for their use | |
MA52906A (fr) | Procédé de préparation d'amg 416 | |
MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation | |
ZA201703443B (en) | Oral rehydration composition and methods thereof | |
EP3341021A4 (fr) | Anticorps anti-alk et leurs procédés d'utilisation | |
IL247315A0 (en) | Anti-acth antibodies and their uses | |
TWI562334B (en) | Semiconductor device and methods for forming the same | |
MA40512A (fr) | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants | |
MA42497A (fr) | Procédés et compositions pour la régulation sélective de l'expression protéique | |
FR3025729B1 (fr) | Ensemble pour le broyage d'echantillons biologiques | |
FR3020758B1 (fr) | Composition pour ameliorer l'hygiene buco-dentaire | |
FR3017378B1 (fr) | Dispositif d'ouvrant pour coffre | |
FI3183568T3 (fi) | Laite objektien fraktioimiseksi ja fraktiointimenetelmä | |
FR3033251B1 (fr) | Treuil d'evacuation en va-et-vient | |
ITUB20153121A1 (it) | Apparato per l'ozonoterapia | |
FR3022149B1 (fr) | Systeme d'haltere reglable | |
FR3019480B1 (fr) | Dispositif anti-vibreur pour l'usinage d'arbre | |
FR3040381B1 (fr) | Systeme pour le prelevement d'articles en stock |